The Political Economy of PFAS: Why It Took 60 Years
PFAS contamination was first documented in the 1970s; the C8 Panel’s internal DuPont and 3M studies linking PFOA and PFOS to health effects date to the 1980s; EPA’s first formal PFOA health advisory came in 2009—decades after internal corporate awareness of risks. Understanding why PFAS regulation was so delayed—and why it has accelerated so dramatically in the past decade—requires examining the political economy of chemical regulation: the power dynamics between industry, government, scientific institutions, and advocacy organizations that determine regulatory outcomes.
The Industry Delay Playbook
Internal corporate documents obtained through litigation reveal that 3M and DuPont employed systematic strategies to delay PFAS regulation: suppression of internal toxicological studies showing health effects; funding of independent scientists and institutions to produce alternative interpretations of the evidence; engagement in EPA regulatory proceedings to extend comment periods and challenge methodologies; lobbying Congress to limit EPA’s regulatory authority under the Safe Drinking Water Act and TSCA; and public communications campaigns emphasizing economic benefits of PFAS while minimizing health risks. These strategies—documented in the “Merchants of Doubt” tradition of corporate science manipulation—delayed meaningful PFAS regulation by 20–30 years compared to the available scientific evidence base.
The Advocacy Ecosystem That Drove Change
The acceleration of PFAS regulation from 2018 to 2024 was not driven primarily by corporate voluntarism or government initiative—it was driven by a sustained advocacy campaign from environmental health organizations, affected community groups, investigative journalists, and scientific advocacy institutions. Key actors: Environmental Working Group (EWG) published the first comprehensive national PFAS database in 2018, creating public awareness through its interactive “tap water database”; Neel Cash’s Dark Waters film brought the DuPont PFOA story to mass audiences; investigative reporting by ProPublica, the Intercept, and the Guardian documented internal corporate documents; the bipartisan Political Action Campaign driven by Congressional representatives from PFAS-affected districts (Michigan, New Hampshire, North Carolina) established PFAS as a legislative priority; and the litigation success of plaintiff attorneys Rob Bilott and others created both financial pressure on industry and public evidentiary record.
The Current Regulatory Landscape: Acceleration and Backlash
The 2022–2024 EPA regulatory acceleration—PFAS Strategic Roadmap, CERCLA designations, NPDWR MCLs—represents a regulatory pendulum swing that was decades in coming. But regulatory acceleration has generated pushback: industry groups have challenged EPA’s NPDWR in federal court, arguing that EPA underestimated compliance costs and overestimated health benefits. The chemical industry’s American Chemistry Council has advocated for risk-based, compound-specific regulation rather than class-based approaches. Political dynamics continue to influence regulatory trajectory: administration changes can alter enforcement priorities, though the legal framework for PFAS MCLs and CERCLA designations now provides regulatory durability beyond any single administration. For the water filtration industry, the current regulatory environment—whatever its political vicissitudes—has established a durable market foundation for PFAS-removal products that will not be reversed.
The PFAS regulatory story is, at its core, a story about how scientific evidence is translated (or suppressed) into policy—and why robust regulatory outcomes require sustained public advocacy, litigation, independent science, and political will in combination with technical evidence.